• A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty 

      Cortés Martínez, Jordi; González Alastrué, José Antonio; Campbell, Michael J.; Cobo Valeri, Erik (2014-10-01)
      Article
      Accés obert
      Objectives: To evaluate the empirical concordance between the hazard ratio (HR) and the median ratio (MR) in survival cancer studies. Study Design and Setting: We selected all cancer survival articles from the New England ...
    • CONSORT 2010 statement: extension to randomised pilot and feasibility trials 

      Eldridge, Sandra; Chan, Claire L; Campbell, Michael J.; Bond, Christine M.; Hopewell, Sally; Thabane, Lethana; Lancaster, Gilian A.; Cobo Valeri, Erik (2016-10-24)
      Article
      Accés obert
      on behalf of the PAFS consensus group authors (listed alphabetically): Doug Altman (address 1), Frank Bretz (2), Marion Campbell (3), Erik Cobo (4), Peter Craig (5), Peter Davidson (6), Trish Groves (7), Freedom Gumedze ...
    • CONSORT 2010 statement: extension to randomised pilot and feasibility trials 

      Eldridge, Sandra; Chan, Claire L; Campbell, Michael J.; Bond, Christine M.; Hopewell, Sally; Thabane, Lethana; Lancaster, Gilian A.; Cobo Valeri, Erik (Springer, 2016-10-21)
      Article
      Accés obert
      The Consolidated Standards of Reporting Trials (CONSORT) statement is a guideline designed to improve the transparency and quality of the reporting of randomised controlled trials (RCTs). In this article we present an ...
    • Does evidence support the high expectations placed in precision medicine? A bibliographic review 

      Cortés Martínez, Jordi; González Alastrué, José Antonio; Medina, María Nuncia; Vogler, Markus; Vilaró Pacheco, Marta; Elmore, Matthew; Senn, Stephen John; Campbell, Michael J.; Cobo Valeri, Erik (2018-01-09)
      Article
      Accés obert
      Background: Precision medicine is the Holy Grail of interventions that aretailored to a patient’s individual characteristics.  However, the conventional design of randomized trials assumes that each individual benefits  ...
    • Germline genetic contribution to the immune landscape of cancer 

      Sayaman, Rosalyn W.; Saad, Mohamad; Thorsson, Vésteinn; Hu, Donglei; Hendrickx, Wouter; Roelands, Jessica; Porta Pardo, Eduard; Mokrab, Younes; Farshidfar, Farshad; Kirchhoff, Tomas; Sweis, Randy F.; Bathe, Oliver F.; Heimann, Carolina; Campbell, Michael J.; Stretch, Cynthia; Huntsman, Scott; Graff, Rebecca E.; Syed, Najeeb; Radvanyi, Laszlo; Shelley, Simon; Wolf, Denise; Marincola, Francesco M.; Ceccarelli, Michele; Galon, Jérôme; Ziv, Elad; Bedognetti, Davide (Elsevier, 2021-02)
      Article
      Accés obert
      Understanding the contribution of the host’s genetic background to cancer immunity may lead to improved stratification for immunotherapy and to the identification of novel therapeutic targets. We investigated the effect ...